Down's syndrome
Jump to navigation
Jump to search
Epidemiology
Pathology
- congenital heart disease
- predisposition to early Alzheimer's disease (AD)
- diffuse amyloid deposits in limbic & association cortex observed in teenage years
- cerebral amyloid angiopathy[20]
- neuritic plaques & neurofibrillary tangles observed in patients in their 30s & 40s
- neuroinflammation, & brain atrophy[20]
- AD pathology observed ONLY when 3 copies of APP gene are present
- ref[13] suggests APP not overexpressed in brain of patients with Down syndrome
Genetics
- trisomy 21
- defects or deficiency of SNX27[8]
- apoE4 allele linked to clinical expression & biomarkers* of Alzheimer's disease[20]
* CSF amyloid-beta, amyloid PET, plasma phosphorylated tau181, cerebral glucose hypometabolism & hippocampal atrophy (carriers vs non-carriers of apoE4 allele)[20]
Clinical manifestations
- hypotonia
- hyperextensible joints
- mongoloid facies
- mental retardation
- protruding tongue
- dementia at an early but variable age (50-70 years)[20]
- earlier frontal lobe manifestations
- social withdrawal
- insomnia
- balance disorder
- emotional lability[5]
- dementia only in 25% of patients by age 60
- premature age-related changes
- early onset menopause
- diabetes mellitus
Laboratory
- amniocentesis with genetic karyotyping
- maternal screen for fetal abnormalities panel in serum/plasma
Complications
- obesity, hypognathia & hypotonia may result in obstructive sleep apnea[5]
- diabetes mellitus type 2
- congenital heart disease,in 1.2-5.2%
- pulmonary-artery hypertension associate with
- obstructive sleep apnea, gastroesophageal reflux,obesity,[16]
- respiratory disease common
- risk of malignancy: acute myeloid leukemia, testicular cancer[16]
- autoimmune disorders
- early mortality
- life expectancy < 60 years[11]; 60 years[18]
- ref[5] implies it is longer
- dementia, functional decline, seizures, visual impairment & institutionalization predict mortality[10]
- ~5-fold risk for COVID-19 hospitalization & ~10-fold risk for COVID-19 mortality[19]
- life expectancy < 60 years[11]; 60 years[18]
* incidence of thyroid disease 50% by age 45 years[16]
Management
- cholinesterase inhibitors not effective for treatment of dementia[5][12]
- may be of some benefit in adolescents[6]
- treat as Alzheimer's disease (low-dose donepezil)[5]
- memantine not effective for treatment of dementia[5][7][12]
- pulsatile GnRH therapy improves cognition & brain connectivity in adults with Down's syndrome[21]
- prognosis
- life expectancy < 60 years[11]; 60 years[18]
- marked racial & temporal differences in prognosis[3]
- caucasian: 50 years (1997); 2 years (1968)
- black:
- 25 years (1997); < 5 years (1985); < 1 year (1967)
- other races: 11 years (1997); < 1 year (1967)
More general terms
Additional terms
References
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 380
- ↑ Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 1038
- ↑ 3.0 3.1 Journal Watch 21(14):116, 2001 MMWR Morb Mortal Wkly Rep 50:463, 2001
- ↑ Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001 Apr;81(2):741-66. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11274343
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019 - ↑ 6.0 6.1 Heller JH et al, Safety and efficacy of rivastigmine in adolescents with Down's syndrome: A preliminary 20-week, open label study. J Child Adolesc Psychopharmacol 2006, 16:755 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17201619
- ↑ 7.0 7.1 Hanney M et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): A randomised, double-blind, placebo-controlled trial. Lancet 2012 Feb 11; 379:528. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22236802
- ↑ 8.0 8.1 Jones MW. Sorting receptors at Down's syndrome synapses. Nat Med. 2013 Apr;19(4):404-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23558625
- ↑ Adorno M, Sikandar S, Mitra SS et al Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature. 2013 Sep 19;501(7467):380-4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24025767
- ↑ 10.0 10.1 Coppus AM1, Evenhuis HM, Verberne GJ et al Survival in elderly persons with Down syndrome. J Am Geriatr Soc. 2008 Dec;56(12):2311-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19093931
- ↑ 11.0 11.1 11.2 Esbensen AJ Health conditions associated with aging and end of life of adults with Down syndrome. Int Rev Res Ment Retard. 2010;39(C):107-126. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21197120
- ↑ 12.0 12.1 12.2 Livingston G, Strydom A. Improving Alzheimer's disease outcomes in Down's syndrome. Lancet. 2012 Feb 11;379(9815):498-500 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22236803
- ↑ 13.0 13.1 Argellati F, Massone S, d'Abramo C et al Evidence against the overexpression of APP in Down syndrome. IUBMB Life. 2006 Feb;58(2):103-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16608822
- ↑ Esbensen AJ. Health conditions associated with aging and end of life of adults with Down syndrome. Int Rev Res Ment Retard. 2010;39(C):107-126. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21197120
- ↑ Esbensen AJ, Mailick MR, Silverman W. Long-term impact of parental well-being on adult outcomes and dementia status in individuals with Down syndrome. Am J Intellect Dev Disabil. 2013 Jul;118(4):294-309. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23937371 Free PMC Article
- ↑ 16.0 16.1 16.2 16.3 Rothaus C Down Syndrome NEJM Resident 360. June 10, 2020 https://resident360.nejm.org/clinical-pearls/down-syndrome
- ↑ Fortea J et al. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. Lancet 2020 Jun 27; 395:1988. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32593336 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30689-9/fulltext
Head E, Ances B. Biomarkers in Down syndrome can help us understand Alzheimer's disease. Lancet 2020 Jun 27; 395:1951 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32593327 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30916-8/fulltext - ↑ 18.0 18.1 18.2 Tsou AY, Bulova P, Capone G et al Medical Care of Adults With Down Syndrome. A Clinical Guideline. JAMA. 2020;324(15):1543-1556. Oct 20, PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079159 https://jamanetwork.com/journals/jama/fullarticle/2771907
Woodward JF, Jan S, Ciccarelli MR. Guidelines for Care of Adults With Down Syndrome. JAMA. 2020;324(15):1509-1511. Oct 20 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079137 https://jamanetwork.com/journals/jama/fullarticle/2771878 - ↑ 19.0 19.1 Clift AK et al COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults. Ann Intern Med 2020. Oct 21 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33085509 https://www.acpjournals.org/doi/10.7326/M20-4986
- ↑ 20.0 20.1 20.2 20.3 20.4 20.5 George J APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome. Earlier Alzheimer's changes seen in APOE4 carriers. MedPage Today July 6, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93442
Bejanin A, Iulita MF, Vilaplana E et al Association of Apolipoprotein E epsilon4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurol. Published online July 6, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34228042 https://jamanetwork.com/journals/jamaneurology/fullarticle/2781524
Lemere CA, Head E, Holtzman DM APOE epsilon4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome - Implications for Clinical Trials and Treatments for All. JAMA Neurol. Published online July 6, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34228117 https://jamanetwork.com/journals/jamaneurology/article-abstract/27815277 - ↑ 21.0 21.1 Manfredi-Lozano M et al. GnRH replacement rescues cognition in Down syndrome. Science 2022 Sep 2; 377:1064. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36048943 https://www.science.org/doi/10.1126/science.abq4515
Patient information
Down's syndrome patient information